Press Release

Ebitda Margin ExpansionExceptional ItemPat Growth 25pctResults View source PDF

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+4.9%1-day move

₹992.00

prior close

₹1036.40

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.6+0.1+0.8-0.8+4.9+4.5+4.7+8.0+8.6+9.1+10.6+8.1+15.8—

Up moveDown movePending

AI summary

Zydus Lifesciences reported strong Q4 FY26 results with revenue up 16% YoY to Rs. 75,870 mn and EBITDA up 20% YoY to Rs. 25,544 mn. EBITDA margin expanded by 110 bps to 33.7%. Net profit grew 15% YoY to Rs. 15,929 mn. For the full year, revenue reached Rs. 271,484 mn (up 17%), EBITDA was Rs. 84,751 mn (up 20%), and net profit was Rs. 54,564 mn (up 15%). The Board recommended 100% dividend and approved a share buyback of up to Rs. 11,000 mn at Rs. 1,150 per share. Exceptional items included Rs. 3,975 mn for Mirabegron litigation settlement. India Formulations grew 14% YoY while Consumer Wellness surged 61% YoY; North America declined 6% YoY.

Likely market impact

Strong operational performance with margin expansion and shareholder returns through dividend and buyback signal financial health. The buyback at 16% premium to market price could provide near-term support to the stock price.